Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer’s disease

Rhonda P. Patrick¹
University of California San Francisco Benioff, Children’s Hospital Oakland Research Institute, Oakland, California, USA

ABSTRACT: Dietary and supplemental intake of the ω-3 fatty acid docosahexaenoic acid (DHA) reduces risk of Alzheimer’s disease (AD) and ameliorates symptoms. The apolipoprotein E (APOE)4 allele is the strongest risk factor for sporadic AD, exclusive of age. APOE4 carriers respond well to the DHA present in fish but do not respond as well to dietary supplements. The mechanisms behind this varied response remain unknown. I posit that the difference is that fish contain DHA in phospholipid form, whereas fish oil supplements do not. This influences whether DHA is metabolized to nonesterified DHA (free DHA) or a phospholipid form called lyso phosphatidylcholine DHA (DHA-lysoPC). Free DHA is transported across the outer membrane leaflet of the blood–brain barrier (BBB) via passive diffusion, and DHA-lysoPC is transported across the inner membrane leaflet of the BBB via the major facilitator superfamily domain-containing protein 2A. I propose that APOE4 carriers have impaired brain transport of free DHA but not of DHA-lysoPC, as a consequence of a breakdown in the outer membrane leaflet of the BBB, putting them at increased risk for AD. Dietary sources of DHA in phospholipid form may provide a means to increase plasma levels of DHA-lysoPC, thereby decreasing the risk of AD.—Patrick, R. P. Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer’s disease. FASEB J. 33, 1554–1564 (2019). www.fasebj.org

KEY WORDS: ω-3 fatty acid · dementia · amyloid-β plaques · tau tangles · phospholipid DHA

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory loss, spatial disorientation, cognitive dysfunction, and behavioral changes. The primary risk factor for sporadic AD is aging, with prevalence roughly doubling every 5 yr after age 65. Approximately one-third of individuals aged 85 and older have AD (1). The major genetic risk factor for late-onset AD is A variant in the apolipoprotein E (APOE) gene called APOE4.

The human APOE gene contains several single nucleotide polymorphisms that result in 3 common APOE isoforms: APOE2, -3, and -4. Approximately 65–80% of all individuals who develop AD carry at least 1 APOE4 allele, a characteristic observed in ~25% of the global population (2). Compared with individuals who have no APOE4 alleles, having 1 APOE4 allele increases AD risk 2–3-fold; carrying 2 APOE4 alleles increases risk as much as 15-fold (3). However, having an APOE4 allele does not necessarily mean that a person will develop AD. Some individuals with an APOE4 allele never get AD, and others who do develop AD do not have any APOE4 alleles (4). Although the presence of the APOE4 allele poses a significantly higher risk for AD and cognitive impairment later in life, it is associated with improved cognition and intelligence in early life, suggesting that the APOE4 allele is an example of antagonistic pleiotropy (5–7).

APOE is widely distributed in both peripheral and brain tissue, where it participates in lipid and cholesterol transport via an LDL receptor-mediated mechanism. Peripheral APOE, which is synthesized primarily in the liver, regulates lipid and cholesterol transport to tissues, and participates in reverse cholesterol transport in plasma. In peripheral tissues, the isoforms of APOE have various effects on lipid metabolism. The APOE3 isoform, considered the benchmark of normal lipid homeostasis, is the standard by which other isoforms are compared. The APOE2 isoform is associated with increased APOE protein expression, increased plasma triglycerides, and decreased plasma cholesterol. The APOE4 isoform is associated with decreased APOE protein expression and increased plasma cholesterol. Brain APOE, which is synthesized primarily by astrocytes, regulates lipid and cholesterol transport to neurons. In the brain, APOE2 and -3 isoforms accumulate in neurons 2–4-fold higher than APOE4, rendering APOE4 less effective at performing its function in the brain (8).

1 Correspondence: UCSF Benioff Children’s Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609, USA. E-mail: rhonda@foundmyfitness.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 2.0 International (CC BY-NC-ND 2.0) (https://creativecommons.org/licenses/by-nc-nd/2.0/) which permits noncommercial use, distribution, and reproduction in any medium, but prohibits the publication/distribution of derivative works, provided the original work is properly cited.

doi: 10.1096/fj.201801412R
PATHOLOGIC HALLMARKS OF ALZHEIMER’S DISEASE

The pathologic hallmarks of AD include extracellular amyloid-β plaques, intracellular neurofibrillary (tau) tangles, and reduced glucose uptake in the brain (Fig. 1). A summary of these hallmarks provides a framework for understanding the disease processes that drive the progression of AD.

**Extracellular amyloid-β plaques**

Normal aging is associated with the accumulation of reactive oxygen species and inflammation in brain tissue, leading to activation of microglial cells, the brain’s resident immune cells. Microglial cells serve an essential role in maintaining brain microenvironment homeostasis. Their activation in the acutely injured brain modulates inflammation and neurotoxicity. In the setting of AD, however, microglial cells are chronically activated by the presence of a 42-aa peptide called amyloid-β42, which results from the cleavage of the full-length amyloid-β protein (9). Chronic microglia activation promotes the production of amyloid-β plaques and initiates a vicious cycle of sustained microglial activation and further production of amyloid-β42 (10). The aggregation of amyloid-β plaques outside of neurons disrupts and destroys synapses between neurons, inhibiting synaptic transmission and inducing neuronal cell death and neurite retraction associated with AD (Fig. 1).

Amyloid-β plaques are cleared from the brain primarily through the glymphatic system and, to a lesser degree, via an APOE-mediated mechanism. The glymphatic system is activated in sleep, during which cerebrospinal fluid diffuses into the brain and carries away waste products including amyloid plaques (11). Poor quality or insufficient sleep prevents glymphatic system activation and leads to greater amyloid plaque accumulation, particularly in APOE4-positive individuals who are unable to clear amyloid peptides via APOE receptor-mediated uptake (12). In APOE-mediated clearance, APOE binds to amyloid-β42 peptide and clears it out of the extracellular space between neurons via the APOE receptor. The APOE4 isoform, however, is unable to clear amyloid-β plaques from the brain because it binds to amyloid-β42 peptide with 20-fold lower affinity than APOE3 (13).

**Intracellular neurofibrillary tangles**

Whereas amyloid-β aggregates outside of neurons, tau, a microtubule-associated protein, aggregates and forms neurofibrillary (tau) tangles inside the neurons in the brains of individuals with AD (Fig. 1). When tau tangles form, the microtubules inside the axon lose stability, thus disrupting the primary system for transporting mitochondria, lipids, and cellular metabolites (9). Cellular energy is thereby reduced, and new synapse formation is halted, resulting in impaired memory, an early hallmark of AD. Eventually, energy levels are insufficient to maintain previously formed synapses, leading to long-term memory deficits, neuronal cell death, and brain atrophy, which are all associated with AD.

**Reduced brain glucose uptake**

Brain glucose uptake and metabolism are impaired in AD (Fig. 1) (14). Metabolic profiling indicates that a subtype of AD specifically associated with decreased brain glucose utilization (15). Carriers of 1 or 2 APOE4 alleles demonstrate decreased brain glucose uptake decades before manifesting clinical features of AD, and individuals with sporadic AD demonstrate decreased brain glucose uptake and increased amyloid plaque deposition comparable to that observed in individuals with autosomal dominant AD mutations, such as amyloid precursor protein, presenilin-1, or presenilin-2 (16, 17).

Glucose enters the brain solely via glucose transporters (GLUTs) resident at the blood–brain barrier (BBB). Brain glucose metabolism is tightly regulated, and neurons are incapable of glucose synthesis or storage. The major GLUTs in the brain are GLUT1 and -3, which do not depend on insulin for glucose uptake and are not insulin sensitive (16, 18). Both GLUT1 and -3 are markedly decreased in the brains of patients with AD carrying an APOE4 allele, compared with healthy individuals without an APOE4 allele (18–20). In mice, GLUT1 deficiency decreases brain glucose uptake and promotes greater accumulation of amyloid plaques, decreases amyloid clearance, and causes widespread neuronal loss and dysfunction consistent with AD (21).
Impaired brain glucose uptake also plays a causal role in formation of tau tangles. Decreased brain glucose uptake impairs attachment of O-linked N-acetylglucosamine (O-GlcNACylation), a post-translational modification of tau protein, leading to tau hyperphosphorylation and subsequent formation of tau tangles (22–24). A possible explanation for the increase in hyperphosphorylated tau in the setting of decreased brain glucose metabolism may be low levels of GLUT1 and -3 transporters. Decreased GLUT1 and -3 diminishes O-GlcNACylation as much as 50% (22, 25, 26) and increases hyperphosphorylation of tau and the quantity of tau tangles in AD brains (18). Furthermore, hyperphosphorylated tau, which promotes formation of tau tangles, exhibits 4-fold less O-GlcNACylation than nonphosphorylated tau in the brains of individuals with AD (25). These data suggest that normal glucose transport into the brain is dependent on GLUT1 and -3 transporters and may be instrumental in preventing hyperphosphorylation of tau protein, the formation of tau tangles, and subsequent development of AD.

**DHA INFLUENCES 3 KEY AD PATHOLOGIES**

Docosahexaenoic acid (DHA) is an essential ω-3 fatty acid that comprises ~30% of the lipids in the human brain. Whereas low levels of DHA promote the 3 pathologies characteristic of AD, normal or high levels prevent or ameliorate them (Fig. 2). Although DHA can be synthesized from plant-derived ω-3 fatty acids, this metabolic pathway is inefficient in humans. As such, most DHA in the human brain is supplied from marine dietary or supplemental sources (27). Supplementation with DHA reduces amyloid-β plaque production, aggregation, and toxicity, and promotes plaque clearance in individuals with moderate dementia and AD (28–30). Furthermore, DHA supplementation decreases tau tangles. Patients with AD who received ~2 g of supplemental DHA for 6 mo exhibited decreased amounts of phosphorylated tau protein in cerebrospinal fluid (31), and nonhuman primates given DHA supplementation demonstrated decreased tau pathology (32). Finally, because DHA is an important component of cell membranes, it facilitates transport of glucose into the brain by regulating GLUT1 transporters (Fig. 2). In rats, DHA deficiency decreases GLUT1 transporters by up to 30% (33, 34), but DHA supplementation increases GLUT1 transporters by 37% and causes endothelial cells to take up more glucose, compared with rodent and nonhuman primate controls (35, 36).

**GENE-DIET INTERACTION: APOE4-DHA**

Healthy diet and lifestyle factors such as sufficient micronutrient status, increased vegetable intake, adequate sleep,
and physical activity decrease AD risk in individuals carrying an APOE4 allele (28–30, 37). In contrast, unhealthy diet and lifestyle factors such as excessive alcohol consumption, low polyunsaturated fat intake, high saturated fat intake, and smoking increase AD risk among APOE4 carriers (38). Dietary fish intake also slows the progression of AD in both APOE4 carriers and noncarriers. Individuals with the APOE4 allele who have high dietary intakes of fish or seafood demonstrate improved brain neuropathology on measures related to AD, including global AD pathology, neuritic plaque density, and AD diagnostic score (39). Patients with AD (both APOE4 carriers and noncarriers) who were treated with a complex dietary and lifestyle protocol that included wild fish experienced a reversal of cognitive decline (28, 40). Dietary intake of fish had no effect in APOE4 carriers in 2 studies, but those studies included <1 serving of fish per week, which may not provide a high enough concentration of ω-3 fatty acids to the brain (41, 42).

The benefits of dietary fish intake on cognitive function in APOE4 carriers have not been observed with DHA supplementation. Multiple studies demonstrate that supplementation with 2 g of DHA per day slows the progression of cognitive decline of AD in APOE4 noncarriers, but has no effect in APOE4 carriers (43, 44). In addition, the positive effects on brain neuropathology observed with high dietary fish intake in APOE4 carriers are not observed with DHA supplementation in APOE4 carriers (39). Furthermore, individuals with the APOE4 allele do not clear amyloid-β plaques after DHA supplementation, and APOE4 impairs DHA transport into the brain, suggesting a possible gene-diet interaction (45, 46).

DHA is critical for preventing or ameliorating the 3 principal pathologies associated with AD. Individuals with APOE4 have increased risk of developing AD and exhibit impaired DHA transport into the brain. Whereas dietary DHA improves AD pathology and reduces AD risk in both APOE4 carriers and noncarriers, DHA supplementation improves AD pathology only in noncarriers. Discerning the mechanisms by which DHA is transported into the brain may be key to understanding the heterogeneous response to DHA supplementation and why the APOE4 allele significantly increases AD risk.

I suggest that APOE4 carriers respond to DHA from fish but not DHA supplements because fish contains DHA in phospholipid form, whereas supplements do not. This difference in form influences whether DHA is metabolized to nonesterified DHA (free DHA) or a specific phospholipid form called lysophosphatidylcholine DHA (DHA-lysoPC). I propose that APOE4 carriers have an impaired brain transport mechanism in free DHA (but not in DHA-lysoPC) that is related to a BBB defect and that puts them at an increased risk for AD because of the accumulation of amyloid β plaques, tau tangles, and low brain glucose levels. I enumerate dietary sources that have greater amounts of DHA in phospholipid form than do fish and suggest that these sources provide a means to increase plasma levels of DHA-lysoPC. Such an increase may allow APOE4 carriers to bypass their defective transport of free DHA and effectively deliver DHA-lysoPC into their brains, thereby lowering their risk of AD.

DHA TRANSPORT INTO THE BRAIN

Even though DHA is abundant in the brain, neurons lack the ability to synthesize it, and although astrocytes are capable of synthesizing DHA from the plant ω-3 fatty acid α-linolenic acid, most DHA must be acquired in the diet and transported from the plasma across the BBB into the brain (47).

DHA is present in 2 major pools in plasma: 1) as components of lipoproteins esterified to triacylglycerol, cholesterol esters, or phospholipids, and 2) bound to albumin, either as nonesterified free DHA or as esterified DHA-lysoPC (48). Approximately 45% of DHA in human plasma is present as free DHA bound to albumin, whereas the remaining 55% is esterified in DHA-lysoPC, most of which is bound to albumin (49). Albumin-bound free DHA and DHA-lysoPC are the only forms of DHA that are transported into the brain; however, they use different transport mechanisms (Fig. 3). Free-DHA is transported across the outer membrane leaflet of the BBB via passive diffusion, and DHA-lysoPC is transported across the inner membrane leaflet of the BBB via the major facilitator superfamily domain-containing protein 2A (MFSD2A) (Fig. 3) (50–52). MFSD2A is a transmembrane protein that is selectively found on endothelial cells that line blood vessels on the BBB (50).

DHA-lysoPC appears to be the brain’s preferred source of DHA (50). Studies demonstrate that DHA-lysoPC accumulates by 10-fold higher amounts in the brains of young rats and piglets, compared with DHA in free fatty acid form (53, 54). After intravenous administration of DHA-lysoPC or free DHA, more DHA-lysoPC is transported into the brain than free DHA (48, 50, 55, 56). Mice engineered to lack the MFSD2A transporter have 60% less DHA in their brains, have small brains, and exhibit a variety of motor and cognitive deficits (50). Humans with a partial or total deficiency in the MFSD2A transporter have impaired brain function that progressively worsens with age, suggesting that DHA-lysoPC transport into the brain is important for maintaining brain function during the aging process (57, 58).

Plasma levels of phosphatidylcholine DHA, which is the precursor to DHA-lysoPC, predict the occurrence of dementia. Approximately 70% of all dementia cases are related to AD (59). Individuals with plasma phosphatidylcholine DHA levels in the highest quartile had a 47% lower risk of dementia than did those with levels in the lower 3 quartiles, independent of the APOE4 allele (59, 60). In addition, low plasma lysosphatidylcholine levels predicted a diagnosis of mild dementia and AD within 2–3 yr with 90% accuracy, independent of the APOE4 allele (61). DHA levels in plasma phospholipids do not differ in APOE4 carriers vs. noncarriers (45). These data suggest that low levels of phosphatidylcholine DHA and lysosphatidylcholine both predict dementia and AD and that the presence of APOE4 does not affect either of these.

IMPAIRED FREE-DHA TRANSPORT INTO THE BRAINS OF APOE4 CARRIERS

Multiple studies demonstrate that APOE4 present in the brain causes a breakdown in BBB integrity, as evidenced
by the disruption of tight junctions and decreased cerebral vascularization (62–65). APOE produced by astrocytes in the brain participates in maintaining the integrity of the tight junctions in the BBB by activating occludin (one of the main components of tight junctions) via an LDL receptor–related protein 1–mediated mechanism (63). However, APOE4 in astrocytes is unable to activate occludin, which leads to degradation of the tight junctions and breakdown of the outer membrane leaflet of the BBB (63). In addition, APOE4 in astrocytes induces breakdown of the BBB caused by microvascular degeneration, basement membrane degradation, and diminished pericyte coverage, all of which progressively worsen with age (64, 65). Furthermore, the basement membrane surface area is reduced in postmortem brains of APOE4 carriers vs. APOE3 carriers (66).

Free-DHA is highly diffusible across the BBB and does not require a transporter to enter the brain (Fig. 3) because of its small size (<500 D), low hydrogen bonding capability, and lipophilicity. It is transported across the outer membrane leaflet of the BBB via passive diffusion, which depends on the integrity of tight junctions and surface permeability, both of which are disrupted by APOE4 produced in astrocytes (59, 61–63). APOE4 also disrupts the passage of other lipophilic compounds that are highly diffusible across the BBB, such as diazepam (59). DHA transport into the brain is disrupted in APOE4 transgenic mice and in APOE4 carriers (45, 46). However, which form of DHA transport, free DHA or DHA-lysoPC, is disrupted remains unknown. I propose that individuals who carry the APOE4 allele have a defect in the transport of free DHA (but not DHA-lysoPC) into the brain because APOE4 causes degradation of tight junctions, which disrupts the outer membrane leaflet of the BBB, but not the inner membrane leaflet (Fig. 4).

The effect of APOE4 produced in astrocytes on impaired transport of DHA and other compounds that are readily transported into the brain via passive diffusion progressively worsens with age (46, 64). This aligns with evidence indicating that the aging process breaks down the integrity of the BBB and disrupts cerebral vascularization similar to the APOE4 allele (67). DHA supplementation does not improve cognitive function in older individuals with APOE4 but does in young APOE4 carriers (43, 68, 69), perhaps because, in younger APOE4 carriers, sufficient free DHA is transported into the brain to positively affect cognitive function; however, as the BBB deteriorates with age, insufficient free DHA is transported into the brain and cognitive function is impaired.

Figure 3. Transport of free DHA and DHA-lysoPC into the brain. Free DHA detaches from albumin in the plasma and is transported along the outer membrane leaflet of the BBB via passive diffusion. APOE3 produced in astrocytes plays a role in maintaining the tight junctions, which keep the outer membrane leaflet of the BBB intact. DHA-lysoPC detaches from albumin and is transported along the inner membrane leaflet of the BBB via the major facilitator superfamily domain-containing MFSD2A, which uses the electrochemical potential of sodium to transfer DHA-lysoPC into the brain.
DHA-lysoPC is another form of DHA that is transported into the brain. Its transport may provide a potential bypass for the BBB defect in APOE4 carriers because in contrast to free DHA transport, DHA-lysoPC is transported through the inner membrane leaflet of the BBB and does not depend on tight junctions, which are disrupted by APOE4 produced in astrocytes (Fig. 4). DHA-lysoPC is transported via the MFSD2A transporter, which uses the electrochemical potential of sodium to transfer DHA-lysoPC across the BBB (Fig. 4). Once DHA-lysoPC reaches the BBB, it detaches from albumin and binds to Mfsd2a, which then transfers it to the inner membrane leaflet of endothelial cells lining the BBB (Fig. 4). This transfer allows DHA-lysoPC to bypass the tight junction defect on the outer membrane leaflet between endothelial cells and to be transported into the brain.

DHA-lysoPC is a dietary bypass for DHA transport across the BBB. The reasons that carriers of the APOE4 allele experience positive effects from dietary DHA intake but experience no benefits from DHA supplementation remain poorly understood. This difference in response most likely occurs because some of the DHA in fish and seafood is present in phospholipid form and maintains this form throughout its metabolic disposition. As such, it can be effectively transported across the BBB as DHA-lysoPC via the MFSD2A transporter (Fig. 4). Fish contain ~1.0–1.5% of their ω-3 fatty acids in phospholipids, whereas fish oil in supplements does not contain any DHA in phospholipid form. Fish roe, in particular, is one of the most concentrated sources of DHA in phospholipid form. The roe from salmon, herring, pollock, and flying fish contain ~38–75% of their ω-3 fatty acids in phospholipid form, mostly present in phosphatidylcholine. Another rich source of DHA...
in phospholipid form is krill oil, which contains ~35% of DHA in phospholipids (72). In contrast, formulations of fish oil supplements containing DHA are generally present as free fatty acids, ethyl esters, and, to a lesser extent, re-esterified triglyceride (73).

DHA is metabolized differently depending on whether it is in phospholipid form (i.e., fish, fish roe, and krill oil), triglyceride form (i.e., fish and some DHA supplements), free fatty acid form (i.e., most DHA supplements), or ethyl ester form (i.e., most DHA supplements) (Fig. 5). A summary of the metabolism of DHA in these various forms provides a useful framework for understanding how DHA present in fish, fish roe, and krill oil may be especially important for delivering DHA-lysoPC into the brains of APOE4 carriers.

**Metabolism of DHA in phospholipid form**

In phospholipids, fatty acids can be attached to the first and second carbons of the glycerol molecule, denoted as the nucleophilic substitution (sn)1 and sn2 positions, respectively. DHA can be attached at the sn1 or -2 position of the glycerol backbone. Most marine sources of fatty acids, such as fish and fish roe, have phosphatidylcholine with DHA at the sn2 position, with a small amount in the sn1 position, with the exception of krill oil, which has a significant amount of phosphatidylcholine with DHA in the sn1 position (74–76). DHA at the sn2 position in phospholipids can be broken down in the intestine by pancreatic phospholipase A2 (PLA2), which releases DHA as free fatty acids. In turn, DHA free fatty acids are resorbed in chylomicrons into both HDL and LDL (77). The pool of DHA that is resorbed into HDL readily forms DHA-lysoPC via the enzyme lecithin-cholesterol acyltransferase (LCAT), whereas the DHA that is resorbed into LDL readily forms free DHA bound to albumin via the enzyme lipase (Fig. 5A) (47, 78, 79). Another enzyme that is present in the plasma that can form DHA-lysoPC is endothelial lipase, which exhibits PLA1 activity and is particularly abundant at the BBB (78). PLA1 catalyzes the hydrolysis of fatty acids to produce a free fatty acid and a lysophospholipid (80).

In contrast to DHA at the sn2 position, DHA at the sn1 position on phospholipids escapes the action of pancreatic PLA2, thus allowing all of the DHA to be retained in phospholipid form and increasing the probability that DHA-lysoPC will be generated (Fig. 5A) (77, 81). DHA in

---

**Figure 5.** Metabolism of phospholipid DHA, ethyl ester DHA, and triglyceride DHA. A) DHA is present on the sn1 and -2 positions of phosphatidylcholine. Human PLA2, present in the intestines, cleaves DHA on the sn2 position, yielding lysophosphatidylcholine with DHA at the sn1 position and free fatty acid DHA (free DHA). The sn1 DHA-lysoPC is resorbed into HDL, forming DHA-lysoPC bound to albumin via the enzyme LCAT. The free fatty acid DHA is resorbed into both LDL and HDL. In LDL, it forms free DHA bound to albumin via the enzyme lipase; in HDL, it forms DHA-lysoPC bound to albumin via LCAT. B) DHA in ethyl ester form is broken down into free fatty acid DHA, which is resorbed into both HDL and LDL. The DHA present in LDL readily forms free DHA bound to albumin, whereas the DHA present in HDL readily forms DHA-lysoPC bound to albumin. C) DHA present in triglyceride form is located at the sn2 position of the triacylglycerol. Human pancreatic lipase generally liberates fatty acids from the sn1 or -3 positions and leaves the sn2 monoglyceride intact. The sn2 monoglyceride is resorbed into both LDL and HDL, where it forms free DHA bound to albumin and DHA-lysoPC bound to albumin, respectively.
the sn1 position of phospholipids is incorporated into phospholipids at a rate ~5-fold higher than DHA in free fatty acid form after absorption. In addition, DHA in the sn1 position of phospholipids accumulates in the HDL fraction by more than 2-fold (77). DHA-lysoPC derives from DHA present in phosphatidylcholine in HDL particles via the actions of LCAT, suggesting that all the DHA at the sn1 position is likely to form DHA-lysoPC (78).

Together, these data suggest that DHA at the sn2 position of phospholipids is metabolized to a free fatty acid DHA, which is then resecreted into both LDL and HDL particles. Only the DHA in HDL forms DHA-lysoPC, however (Fig. 5A). The DHA in LDL forms free DHA; only a portion of the DHA at the sn2 position of phospholipids forms DHA-lysoPC. In contrast, all of the DHA at the sn1 position retains its phospholipid form and is incorporated into HDL particles, thus forming even more DHA-lysoPC (Fig. 5A).

**Metabolism of DHA in ethyl ester and triglyceride form**

In contrast to the DHA present in fish, fish roe, and krill oil, DHA from fish oil supplements is mostly present in the ethyl ester form, free fatty acid form, or, to a lesser extent, the re-esterified triglyceride form and is mostly broken down by pancreatic lipases in the intestines (73). In triglycerides, fatty acids can be attached to the first, second, or third carbons of the glycerol molecule, denoted as the sn1, -2, or -3 positions, respectively. DHA can be attached at any of these positions on the glycerol backbone. DHA in ethyl ester form is broken down into free fatty acid DHA, which is resecreted in chylomicrons into both HDL and LDL (Fig. 5B) (77). The DHA present in LDL readily forms free DHA, whereas the DHA present in HDL readily forms DHA-lysoPC (Fig. 5B) (47, 78, 79). The DHA found in fish or fish oil supplements in triglyceride form is mostly located at the sn2 position of the triacylglycerol (Fig. 5C) (82). However, human pancreatic lipase generally liberates DHA from the sn1 or -3 positions and leaves the sn2 monoglyceride intact (83). The sn2 monoglyceride is resecreted in chylomicrons into both HDL and LDL (Fig. 5C). DHA in triglyceride form from either fish or fish oil supplements accumulates in plasma phospholipids 4-fold higher than DHA in ethyl ester form (73).

These data suggest that DHA has a different metabolic fate, depending on whether it originates from phospholipids, ethyl esters, or triglycerides (Fig. 5). Similar to DHA at the sn2 position in phospholipids, the DHA in ethyl ester form is metabolized to free fatty acid DHA, which ultimately can form both DHA-lysoPC and free DHA bound to albumin. DHA present in triglyceride form is metabolized to sn2 monoglyceride, is resecreted in chylomicrons into both HDL and LDL, and ultimately forms both DHA-lysoPC and free DHA bound to albumin. However, phospholipids also have DHA at the sn1 position, where it retains its phospholipid form and only forms DHA-lysoPC, therefore making DHA in phospholipid form a better source of DHA-lysoPC (Fig. 5). However, since DHA in both triglyceride and ethyl ester forms can generate DHA-lysoPC, it remains possible that a higher dose of DHA in those forms may markedly increase the DHA-lysoPC pool.

### Plasma levels of DHA-lysoPC from DHA in phospholipid vs. triglyceride

The metabolic disposition of DHA in the phospholipid form occurs more rapidly than that of the triglyceride form. For example, when humans consume DHA in phospholipid form, albumin-bound DHA-lysoPC appears in plasma faster than when they consume DHA in triglyceride form (81, 84). In addition, red blood cell quantitites of DHA-lysoPC, a biomarker for brain DHA levels, increase (49). Individuals who received an oral dose of phospholipid DHA demonstrated higher DHA uptake in red blood cells compared with those given an oral dose of DHA in triglyceride form (81, 84). Humans who consume fish oil consisting of DHA in triglyceride form exhibit an increase in free DHA bound to albumin but a slower appearance of DHA-lysoPC 2 h later (49, 84). In addition, more DHA is delivered to the brain when it is consumed in phospholipid form than when it is consumed in triglyceride form. Rats that were fed radiolabeled DHA in phospholipid form exhibited 78% more DHA in the cerebellum, 140% more DHA in the hippocampus, and 69% more DHA in the remainder of the brain after 6 h compared with rats fed DHA in triglyceride form (85). Furthermore, oral DHA-lysoPC given to mice increased brain DHA levels 2-fold and improved spatial learning and memory, whereas free DHA did not (86). These data suggest that consuming DHA in phospholipid form (i.e., fish, fish roe, krill oil) increases the formation of DHA-lysoPC in plasma, and more DHA is taken up by the brain compared with DHA consumed in triglyceride form (i.e., DHA supplements, fish).

### DISCUSSION

Based on several independent lines of evidence, I suggest that the reason individuals with an APOE4 allele have improved cognitive function with fish intake but not with DHA supplementation is that fish contains DHA in phospholipid form, whereas supplements do not. This difference in form influences whether DHA is metabolized to plasma free DHA or a specific phospholipid form called DHA-lysoPC. I propose that APOE4 carriers have impaired brain transport of free DHA but not DHA-lysoPC as a consequence of a breakdown in BBB integrity. This impaired transport puts them at an increased risk for AD caused by the accumulation of amyloid β plaques, tau tangles, and low brain glucose levels. Dietary sources that contain high amounts of DHA in phospholipid form may provide a means to increase plasma levels of DHA-lysoPC. Such an increase may allow APOE4 carriers to bypass their defective transport of free DHA and effectively deliver DHA-lysoPC into their brains, thereby lowering their risk of AD.
This proposal is derived from the following observations: 1) APOE4 carriers have improved brain neuropathology and cognitive function with high dietary fish intake, but not with DHA supplementation; 2) after DHA supplementation, humans and mice carrying the APOE4 allele have decreased DHA transport into the brain, which progressively worsens with age; 3) APOE4 in astrocytes inhibits occludin activation, which leads to degradation of the tight junctions, breakdown of the outer membrane leaflet of the BBB, and morphologic disturbances, including diminished cerebral vascularization, leading to BBB dysfunction; 4) free DHA is highly diffusible across the BBB and is transported along the outer membrane leaflet of the BBB, but this process is disrupted by tight junction degradation caused by APOE4 produced in the brain; 5) transport of DHA-lysoPC into the brain does not depend on tight junctions in the BBB, but instead is transported along the inner membrane leaflet via the MFSD2A transporter, which uses the electrochemical potential of sodium to transfer DHA-lysoPC into the brain; 6) fish, fish roe, and krill oil contain DHA in phospholipid form to various extents, whereas DHA supplements contain DHA in triglyceride or ethyl ester form; 7) more DHA in phospholipid form appears in the plasma as DHA-lysoPC compared with DHA in triglyceride form or ethyl ester form; and 8) more DHA is taken up by the brain when DHA is consumed in phospholipid form compared with DHA consumed in triglyceride form. All clinical trials to date that have evaluated the effect of DHA on cognitive function and brain morphology, separately or together, in patients with AD with an APOE4 allele have used fish oil supplements, which do not contain DHA in phospholipid form. When DHA is consumed in phospholipid form (as from dietary fish or seafood) more DHA appears in the plasma as DHA-lysoPC, which may be better transported across the BBB of APOE4 carriers. There is a pressing need for clinical trials evaluating the effects of ω-3 in phospholipid form, either from fish roe oil or krill oil, on cognitive function in APOE4 carriers with AD.

ACKNOWLEDGMENTS

The author thanks Bruce Ames (University of California San Francisco Benioff Children’s Hospital Oakland Research Institute), Giovanna Ferro-Luzzi Ames, Teresa L. Johnson, Daniel Patrick, and Robert Ryan (University of Nevada, Reno, NV, USA) for comments, editing, and suggestions on the manuscript, and Alison Gates for assistance during drafting of the figures. R.P.P. is grateful for the support of financial contributors to her website FoundMyFitness.com, and to the Children’s Hospital Oakland Research Institute (CHORI)–Ames Supporting Foundation for financially sustaining her during different periods of the drafting of this manuscript. R.P.P. produces a web-based podcast series and provides single nucleotide polymorphism–related resources that help listeners identify their individual genotypes from raw data provided by consumer genetic testing services. The author declares no conflicts of interest.

AUTHOR CONTRIBUTION

R. P. Patrick is the sole author of this manuscript.

REFERENCES

1. Alzheimer’s Association. (2015) 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 11, 332–384
2. Huang, Y. (2011) Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer’s disease: lessons from ApoE mouse models. Biochem. Soc. Trans., 39, 924–932
3. APOE and Alzheimer Disease Meta-Analyses Consortium. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 278, 1349–1356
4. Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., and Cummings, J. L. (2015) Alzheimer’s disease. Nat. Rev. Dis. Primers 1, 15056
5. Jochemsen, H. M., Muller, M., van der Graaf, Y., and Geerlings, M. I. (2012) APOE e4 differentially influences change in memory performance depending on age: the SMART-MR study. Neurobiol. Aging 33, 832.e15–832.e22
6. Mondadori, C. R., de Quervain, D. J., Buchmann, A., Mustovic, H., Wollmer, M. A., Schmidt, C. F., Boesiger, P., Hock, C., Nitsch, R. M., Papassoitropoulos, A., and Henke, K. (2007) Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb. Cortex 17, 1954–1947
7. Yu, Y. W., Lin, C. H., Chen, S. P., Hong, C. J., and Tsai, S. J. (2000) Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. Neurosci. Lett. 294, 179–181
8. Hauser, P. S., Narayanawami, V., and Ryan, R. O. (2011) Apolipoprotein E: from lipid transport to neurobiology. Prog. Lipid Res. 50, 62–74
9. Serrano-Pozo, A., Frosch, M. P., Masliah, E., and Hyman, B. T. (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189
10. Solito, E., and Sastre, M. (2012) Microglia function in Alzheimer’s disease. Front. Pharmacol. 3, 14
11. Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Ruisinek, H., Nicholson, C., Zlokovic, B. V., Frangione, B., Blennow, K., Menard, J., Zetterberg, H., Wisniewski, T., and Jonsson, M. J. (2015) Clearance systems in the brain-imPLICATIONS for Alzheimer disease. Nat. Rev. Neuro. 11, 457–470; erratum: 12, 248
12. Lim, A. S., Kowgier, M., Yu, L., Buchman, A. S., and Bennett, D. A. (2013) Sleep fragmentation and the risk of incident Alzheimer disease and cognitive decline in older persons. Sleep (Baltimore) 36, 1027–1032
13. Kanekiyo, T., Xu, H., and Bu, G. (2014) APOE and AB in Alzheimer’s disease: accidental encounters or partners? Neuron 81, 740–754
14. Nordberg, A., Rinne, J. O., Kadir, A., and L¨angstr¨om, B. (2010) The use of PET in Alzheimer disease. Nat. Rev. Neurol. 6, 78–87
15. Breeden, D. E. (2015) Metabolic profiling distinguishes three subtypes of Alzheimer’s disease. Aging (Albany N.Y.) 7, 593–600
16. Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblier, S., Castellano, A., Pifferi, F., Bocci, F., Paquet, N., Begdouri, H., Bentourkia, M., Turcotte, E., Allard, M., Barberge-Gateau, P., Fulop, T., and Raponiot, S. I. (2011) Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 27, 3–20
17. Rodríguez-Vieitez, E., Saint-Aubert, L., Carter, S. F., Almkvist, O., Frangione, B., Blennow, K., Menard, J., Zetterberg, H., Wisniewski, T., and Jonsson, M. J. (2013) Sleep fragmentation and the risk of incident Alzheimer disease and cognitive decline in older persons. Sleep (Baltimore) 36, 1027–1032
18. Liu, Y., Liu, F., Eqbal, K., Grundke-Iqbal, I., and Gong, C. X. (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 582, 359–364
19. Simpson, I. A., Chumdu, K. R., Davies-Hill, T., Honer, W. G., and Davies, P. (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann. Neurol. 35, 546–551
20. Mooradian, A. D., Chung, H. C., and Shah, G. N. (1997) GLUT-1 dysfunction in young apolipoprotein E epsilon4 carriers. Cereb. Cortex 17, 1954–1947
21. Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hilliman, S., Kong, P., Nelson, A. R., Sullivan, J. S., Zhao, Z., Meiselman, H. J., Wandy, R. B., Soto, J., Abel, E. D., Makshanoff, J., Zuniga, E., De Vivo, D. C., and Zlokovic, B. V. (2015) GLUT1 reductions exacerbate Alzheimer’s disease vascular-neuronal dysfunction and degeneration. Nat. Neurosci. 18, 591–590
DHA AND APOE4-ASSOCIATED ALZHEIMER'S DISEASE

22. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., and Gong, C. X. (2004) Docosahexaenoic acid acylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **101**, 10804–10809

23. Li, X., Liu, F., Wang, J. Z., and Gong, C. X. (2006) Concurrent alterations of ω-3 GLNacylation and phosphorylation of tau in mouse brains during fasting. *Eur. J. Neurosci.* **23**, 2078–2086

24. Deng, Y., Li, B., Liu, F., Grundke-Iqbal, I., Brandt, R., and Gong, C. X. (2008) Regulation between GLNacylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. *FASEB J.* **22**, 138–145

25. Liu, S., S., Tanimukai, H., Gu, J., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2009) Reduced GLNacylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. *Brain* **132**, 1829–1832

26. Smith, J. C., Nielson, K. A., Woodard, J. L., Seidenberg, M., Durgerian, S., Zhang, X., Wenk, M. R., Goh, E. L., and Silver, D. L. (2014) Mfsd2a is a preferred carrier form of docosahexaenoic acid to the brain. *Neurochem. Res.* **39**, 1327–1339

27. Burdge, G. C., and Calder, P. C. (2006) Dietary α-linolenic acid and APOE4-associated Alzheimer's disease. *Aging (Albany N.Y.)** 8**, 25–32

28. Bredesen, D., E., Amos, E. C., Canick, J., Ackerley, M., Raji, C., Fiala, M., and Ahdidan, J. (2016) Reversal of cognitive decline in Alzheimer's disease: a targeted dietary therapeutic intervention. *J. Alzheimers Dis.* **50**, 9–13

29. Bredesen, D. E. (2014) Reversal of cognitive decline: a novel therapeutic program. *Aging (Albany N.Y.)** 6**, 707–717

30. Smith, J. C., Nielson, K. A., Woodard, J. L., Seidenberg, M., Durgerian, S., Hazlett, K. E., Figueuira, C. M., Kandahl, C. C., Kay, C. D., Matthews, M. A., and Rao, S. M. (2014) Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease. *Front Aging Neurosci.* **6**, 61

31. Freund Levi, Y., Vedin, I., Cederholm, T., Basun, H., Faxén Irving, G., Smith, J. C., Nielson, K. A., Ellis, L., and LaFerla, F. M. (2007) Dietary docosahexaenoic acid decreases β-amyloid plaque and brain barrier. *Prostaglandins Leukot. Essent. Fatty Acids* **77**, 279–286

32. Green, K. N., Martínez-Coría, H., Khashew, H., Hall, E. B., Yurko-Mauro, K. A., Ellis, L., and LaFerla, F. M. (2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. *J. Neurosci.* **27**, 4395–4395

33. Pifferi, F., Roux, F., Langelier, B., Alessandri, J. M., Vancassel, S., Jouin, M., Lavialle, M., and Guinouet, P. (2005) n-3 polyunsaturated fatty acids and APOE4 status with brain neurotrophin expression and cognitive decline in Alzheimer disease: a population-based study. *J. Cell. Mol. Med.* **12** (6B), 2762–2771

34. Smith, J. C., Nielson, K. A., Woodard, J. L., Seidenberg, M., Durgerian, S., Antuono, P., Butts, A. M., Hanke, N. C., Lancaster, M. A., and Rao, S. M. (2011) Interactive effects of physical activity and APOE ε4 on BOLD semantic memory activation in healthy elders. *Neuroimage* **54**, 650–664

35. Kivipelto, M., Ngandu, T., Kivits, I., Kivits, I., Kivits, I., Tuomilehto, J., and Soininen, H. (2011) The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease. *Alzheimers Res. Ther.* **8**, 5

36. Barberger-Gateau, P., Raffaitin, C., Letenneur, L., Berr, C., Tzourio, C., Dartigues, J. F., and Poirier, P. (2007) Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology* **69**, 1921–1930

37. Quínn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Gahm, J. E., Emond, J., Jack, C. R. Jr., Weinier, M., Shintu, L., and Aisen, P. S. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* **304**, 1905–1911

38. Kivipelto, M., Rovio, S., Ngandu, T., Kiss, P., Kivits, I., Tuomilehto, J., and Soininen, H. (2011) Reversal of cognitive decline in Alzheimer’s disease: a targeted dietary intervention. *J. Neurochem.* **118**, 2086–2099

39. Cazeneuve-Gassiot, A., Chiche, I., Bousquet, J., Cowdrey, M., Thévenin, D., and Leboyer, M. (2016) Association of seafood consumption, brain morphology and the APOE status in elderly participants of the 3C Cohort Study. *Neuropsychobiology* **73**, 161–168

40. Thévenin, D., Bousquet, J., Cheynier, V., and Leboyer, M. (2016) Peripheral biomarkers of dietary intake in the 3C Cohort Study: influence of brain nutrients on peripheral biomarkers and associations with brain measures. *Neuropsychobiology* **73**, 169–179

41. Schaefer, E. J., Bongard, V., Beiser, A. S., Lemmon-Foisy, S., Robins, S. J., Au, R. H., Tucker, K. L., Kyle, D. J., Wilson, P. W., and Wolf, P. A. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of cognitive decline in older adults. *Aging (Albany N.Y.)** 8**, 25–32

42. Barberger-Gateau, P., Raffaitin, C., Letenneur, L., Berr, C., Tzourio, C., Dartigues, J. F., and Poirier, P. (2007) Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology* **69**, 1921–1930

43. Quínn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Gahm, J. E., Emond, J., Jack, C. R. Jr., Weinier, M., Shintu, L., and Aisen, P. S. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* **304**, 1905–1911

44. Cazeneuve-Gassiot, A., Chiche, I., Bousquet, J., Cowdrey, M., Thévenin, D., and Leboyer, M. (2016) Association of seafood consumption, brain morphology and the APOE status in elderly participants of the 3C Cohort Study. *Neuropsychobiology* **73**, 161–168

45. Schaefer, E. J., Bongard, V., Beiser, A. S., Lemmon-Foisy, S., Robins, S. J., Au, R. H., Tucker, K. L., Kyle, D. J., Wilson, P. W., and Wolf, P. A. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of cognitive decline in older adults. *Aging (Albany N.Y.)** 8**, 25–32

46. Barberger-Gateau, P., Raffaitin, C., Letenneur, L., Berr, C., Tzourio, C., Dartigues, J. F., and Poirier, P. (2007) Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology* **69**, 1921–1930

47. Quínn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Gahm, J. E., Emond, J., Jack, C. R. Jr., Weinier, M., Shintu, L., and Aisen, P. S. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* **304**, 1905–1911

48. Cazeneuve-Gassiot, A., Chiche, I., Bousquet, J., Cowdrey, M., Thévenin, D., and Leboyer, M. (2016) Association of seafood consumption, brain morphology and the APOE status in elderly participants of the 3C Cohort Study. *Neuropsychobiology* **73**, 161–168

49. Schaefer, E. J., Bongard, V., Beiser, A. S., Lemmon-Foisy, S., Robins, S. J., Au, R. H., Tucker, K. L., Kyle, D. J., Wilson, P. W., and Wolf, P. A. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of cognitive decline in older adults. *Aging (Albany N.Y.)** 8**, 25–32
of dementia and Alzheimer disease: the Framingham Heart Study. *Arch. Neurol.* 63, 1545–1550

60. Mulder, M., Ravid, R., Swaab, D. F., de Kloet, E. R., Haasdijk, E. D., Juk, J., van der Boom, J. J., and Havekes, L. M. (1998) Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. *Alzheimer Dis. Assoc. Disord.* 12, 198–203

61. Mapstone, M., Cheema, A. K., Fandaca, M. S., Zhong, X., Mhuye, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., Nazar, M. D., Rich, S. A., Berlau, D. J., Peltz, C. B., Tan, M. T., Kawas, C. H., and Fedoroff, H. J. (2014) Plasma phospholipids identify antecedent memory impairment in older adults. *Nat. Med.* 20, 415–418

62. Halliday, M. R., Pomarà, N., Sagare, A. P., Mack, W. J., Frangione, B., and Zlokovic, B. V. (2015) Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. *JAMA Neurol.* 70, 1198–1200

63. Nishitsuji, K., Hosono, T., Nakamura, T., Bu, G., and Michikawa, M. (2011) Apolipoprotein E controls cerebrovascular apolipoprotein E4 expression impairs cerebral vascularization and blood-brain barrier function in mice. *J. Cereb. Blood Flow Metab.* 31, 96–104

64. Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Besholtz, C., Armulk, A., Sallstrom, J., Berk, B. C., and Zlokovic, B. V. (2012) Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. *J. Biol. Chem.* 286, 17536–17542

65. Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Pomarà, N., Sagare, A. P., Mack, W. J., Frangione, B., and Zlokovic, B. V. (2015) ApoE controls cerebrovascular integrity via cyclophilin A. *Nature* 485, 512–516

66. Salloway, S., Gur, T., Berzin, T., Tavares, R., Zipser, B., Correia, S., Bell, R. D., Winkel, E. A., Singh, I., Sagare, A. P., Dean, R., Wu, Z., Holtzman, D. M., Besholtz, C., Armulk, A., Sallstrom, J., Berk, B. C., and Zlokovic, B. V. (2012) Apolipoprotein E controls cerebrovascular integrity in models with astrocyte barrier breakdown. *JAMA Neurol.* 70, 1198–1200

67. Watkins, B., Hoem, N., Tavares, R., Bu, G., and Michikawa, M. (2011) Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. *J. Biol. Chem.* 286, 17536–17542

68. Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., Harrington, M. G., Chui, H. C., Law, M., and Zlokovic, B. V. (2015) Blood-brain barrier breakdown in the aging human hippocampus. *Neuron* 85, 296–302

69. Stonehouse, W., Conlon, C. A., Podd, J., Hill, S. R., Minihane, A. M., Haskell, C., and Kennedy, D. (2013) DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. *Int. J. Mol. Sci.* 15, 15401–15419

70. Dyerberg, J., Madsen, P., Møller, J. M., Aardestrup, I., and Schmidt, E. B. (2010) Bioavailability of marine n-3 fatty acid formulations. *Prostaglandins Leukot. Essent. Fatty Acids* 83, 137–141

71. Chen, S., Belikova, N. A., and Subbaiah, P. V. (2012) Structural elucidation of molecular species of pacific oyster ether amino phospholipids by normal-phase liquid chromatography/negative-ion electrospray ionization and quadrupole/multiple-stage linear ion-trap mass spectrometry. *Anal. Chim. Acta* 735, 76–89

72. Chen, S., and Li, K. W. (2008) Comparison of molecular species of various transphosphatidylated phosphatidylethanolamine (PE) with bovine cortex PS by mass spectrometry. *Chem. Phys. Lipids* 152, 46–56

73. Taylor, J. L., and Lagarde, M. (1997) Human plasma albumin containing DHA and their potential to deliver DHA to the brain: role of the enzyme in the delivery of docosahexaenoic acid (DHA) to tissues. *Biochim. Biophys. Acta 1771*, 1319–1328

74. Chen, S., and Subbaiah, P. V. (2013) Reoxygenosors of phosphatidylcholine containing DHA and their potential to deliver DHA to the brain: role of phospholipase specificities. *Lipids* 48, 675–686

75. Lemaitre-Delaunay, D., Pachiaudi, C., Laville, M., Pousin, J., Armstrong, M., and Lagarde, M. (1999) Blood compartmental metabolism of docosahexaenoic acid (DHA) in humans after ingestion of a single dose of [13C]DHA in phosphatidylcholine. *J. Lipid Res.* 40, 1867–1874

76. Ruiz-Lopez, N., Stubbah, I., Ishharguerrue, I., Rimbach, G., and Menozy, D. (2015) Positional distribution of fatty acids in triacylglycerols and phospholipids from fillets of Atlantic salmon (Salmo salar) fed vegetable and fish oil blends. *Mar. Drugs* 13, 4255–4269

77. Tso, P., and Hayashi, H. (1989) The physiology and regulation of the intestinal absorption and transport of omega-3 and omega-6 fatty acids. *Adv. Prostaglandin Thromboxane Leukot. Res.* 19, 623–626

78. Richo, C., and Brossard, N. (2017) Dietary docosahexaenoic acid (DHA) in phospholipids or dietary docosahexaenoic acid (DHA) in phospholipids or triglycerides on brain DHA uptake and accretion. *J. Nutr. Biochem.* 33, 91–102

79. Suganum, N., Thomas, R., Yalgalda, P. C. R., Tai, L. M., and Subbaiah, P. V. (2017) Dietary docosahexaenoic acid (DHA) as lysophosphatidylcholine, but not as free acid, enriches brain DHA and improves memory in adult mice. *Sci. Rep.* 7, 11263

Received for publication July 9, 2018. Accepted for publication September 10, 2018.